what is cryptocurrency based on snippets

Shenzhen Holdings: Auditor replacement: PricewaterhouseCoopers resigned and Ernst & Young took over. On December 10th, Shenzhen Holdings (00604.HK) announced that according to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, PricewaterhouseCoopers agreed to resign as the auditor of Shenzhen Holdings with effect from December 10th, 2024. At the same time, the board of directors of Shenzhen Holdings decided to appoint Ernst & Young as the new auditor of the company, which will also take effect from December 10, 2024 until the end of the next annual general meeting.Everbright Securities: The effect of trade-in subsidy for the whole year is much better than expected. Everbright Securities released a research report saying that the Politburo proposed to implement more relaxed policies, vigorously boost consumption and lead the development of new quality productivity. The intelligent direction of the automobile industry not only conforms to the development tone, but also plays an important role in boosting consumption. At the same time, the industry involves the "two new" themes of large-scale equipment renewal and trade-in of consumer goods, and the bank continues to be optimistic about investment opportunities in the automobile sector driven by favorable policies.Trump appointed TOM BARRACK as the US ambassador to Turkey.

The chief operating officer of BlackRock seeks to improve its technical and artificial intelligence capabilities. The chief operating officer of BlackRock, the world's largest asset management company, said on Tuesday that the company is looking for opportunities to expand its technical capabilities, including in the field of artificial intelligence. Rob Goldstein, chief operating officer of BlackRock, said in an interview at a conference in new york: "There are always some capabilities that can be improved."Huatai Securities: The policy overweight boosts consumption and is optimistic about the four main lines. Huatai Securities Research Report said that with the continuous efforts of promoting consumption policies, the large consumer sector ushered in the configuration window period and continued to be optimistic about the basic orientation and valuation repair of the consumer sector. It is suggested to pay attention to four main investment lines: 1) the rise of domestic products: the strength and brand power of domestic products in beauty care, home appliances, pets, textiles and clothing are constantly improving, occupying consumers' minds against the trend, and domestic products continue to lead; 2) Emotional consumption: the products on the supply side are continuously iterated, and the goods/services are built as a medium to convey emotional value, and the consumption on the demand side is superimposed to promote the continuous expansion of the tide play /IP economy; 3) New cost performance: The consumption concept of residents is becoming more and more rational, and the quality-price ratio has become the core of consumption decision-making. The new cost performance consumption focusing on "good but not expensive" is expected to continue to grow rapidly; 4) Consumption going to sea: Going to sea has become a necessary topic for consumer enterprises. Under the two-way catalysis of supply and demand, China enterprises are actively participating in global market competition and paying attention to brand/culture/service going to sea.13 shares registered today, Hengxuan Technology, Xiamen Bank and Deshi shares have the strongest dividends. According to the statistics of the equity distribution plan of listed companies, 13 A shares registered today. Among them, 13 shares intend to pay dividends. In terms of dividends, 13 stocks paid dividends in date of record on December 11th. Hengxuan Technology, Xiamen Bank and Deshi Co., Ltd. have the strongest dividends, with dividends of 7.60 yuan for every 10 shares, 1.5 yuan and 1.2 yuan respectively. In addition, there are 5 shares that have thrown out dividend payout plans, among which Contemporary Amperex Technology Co., Limited, Taotao Auto Industry and Hite Bio have the strongest dividend payout, with dividends of 12.3 yuan for every 10 shares, 5 yuan and 1.3 yuan respectively.

Ministry of Finance of the Republic of Korea: We will pay close attention to the financial and foreign exchange market trends and take adequate measures to curb excessive fluctuations in the foreign exchange market.Desai Siwei and Infineon jointly set up an innovative application center. Recently, the signing and unveiling ceremony of Desai Siwei-Infineon innovative application center and the signing ceremony of the memorandum of cooperation on intelligent driving domain control were held in Huizhou. At present, Desai Siwei and Infineon are relying on the Innovation Application Center to jointly define the MCU chip architecture of the future EEA, test the performance and evaluate the reliability of TC4x MCU devices, so as to provide innovative solutions to customers. In the future, Desai Siwei will join hands with Infineon to carry out joint technical research in two key areas: intelligent driving and cockpit, and accelerate the commercialization of more innovative product technical solutions.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.